In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dermal fillers on FDA’s radar

This article was originally published in The Gray Sheet

Executive Summary

Agency is putting together a "Post Market Issue Action Team" to address complaints about the long-term effects of dermal fillers, Peter Rumm, deputy director of general, restorative and neurological devices at the Office of Device Evaluation, says Sept. 17. Allergan gained expanded labeling in June for treatment effects lasting up to one year with its Juvederm Ultra and Juvederm Ultra Plus dermal fillers (1"The Gray Sheet" July 2, 2007, In Brief). BioForm Medical (Radiesse) and Artes Medical (ArteFill) are among other firms seeking longer-lasting indications

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts